HAEMOPHILIA : NOVOSEVEN® SHOULD BE GIVEN AS EARLY AS POSSIBLE AFTER THE START OF A BLEEDING EPISODE. THE RECOMMENDED INITIAL DOSE, ADMINISTERED BY INTRAVENOUS BOLUS INJECTION, IS 90 µG PER KG BODY WEIGHT. DOSE INTERVAL - INITIALLY 2-3 HOURS TO OBTAIN HAEMOSTASIS. IF CONTINUED THERAPY IS NEEDED, THE DOSE INTERVAL CAN BE INCREASED SUCCESSIVELY ONCE EFFECTIVE HAEMOSTASIS IS ACHIEVED TO EVERY 4, 6, 8, OR 12 HOURS FOR AS LONG AS TREATMENT IS JUDGED AS BEING INDICATED.
FACTOR VII DEFICIENCY : RECOMMENDED DOSE RANGE FOR TREATMENT OF BLEEDING EPISODES IN PATIENTS UNDERGOING SURGERY OR INVASIVE PROCEDURES IS 15-30 µG PER KG BODY WEIGHT EVERY 4-6 HOURS UNTIL HAEMOSTASIS IS ACHIEVED. DOSE AND FREQUENCY OF INJECTIONS SHOULD BE ADAPTED TO EACH INDIVIDUAL.
GLANZMANNS THROMBASTHENIA : RECOMMENDED DOSE FOR TREATMENT OF BLEEDING EPISODES AND FOR THE PREVENTION OF BLEEDING IN PATIENTS UNDERGOING SURGERY OR INVASIVE PROCEDURES IS 90 µG (RANGE 80-120 µG) PER KG BODY WEIGHT AT INTERVALS OF TWO HOURS (1.5 - 2.5 HOURS). AT LEAST THREE DOSES SHOULD BE ADMINISTERED TO SECURE EFFECTIVE HAEMOSTASIS. THE RECOMMENDED ROUTE OF ADMINISTRATION IS BOLUS INJECTION AS LACK OF EFFICACY MAY APPEAR IN CONNECTION WITH CONTINUOUS INFUSION.
FOR THOSE PATIENTS WHO ARE NOT REFRACTORY, PLATELETS IS THE FIRST LINE TREATMENT FOR GLANZMANN'S THROMBASTHENIA.
LABORATORY COAGULATION PARAMETERS MAY BE USED AS AN ADJUNCT TO THE CLINICAL EVALUATION OF HAEMOSTASIS FOR MONITORING THE EFFECTIVENESS AND TREATMENT SCHEDULE OF NOVOSEVEN : ASSAYS OF PROTHROMBIN TIME (PT), ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT), AND PLASMA FVII CLOTTING ACTIVITY (FVII:C).